Table 1.

Patient characteristics

FtoM (n = 315)MtoF (n = 260)Matched (n = 557)
BM, nPBSCs, nPBM, nPBSCs, nPBM, nPBSCs, nP
Patient age, y.80.59.45
 <5057128.8054109118242
 ≥503892366158139
Donor age, y.711.00.35
 <505913162116116234
 ≥503689285460146
Performance status1.00.231.00
 0-19221188159169365
 2-439210716
CMV serostatus.01.52.36
 No324416384073
 Yes5715869127127287
Disease.18.25.69
 AML52102398078161
 ALL235926434196
 Lymphoma63110303178
 CML, MPD, MDS142815172646
rDRI.64.33.41
 Low14247182051
 Intermediate7317578135147304
 High818415622
HCT-CI.57.55.11
 06413466113128244
 1-2215514343586
 ≥392810231347
GVHD prophylaxis.07.03.01
 Cyclosporine based7815476122135266
 Tacrolimus based1458124535112
 Other382363
Conditioning.66.65.59
 Cyclophosphamide + TBI4288376876148
 Busulfan + cyclophosphamide143515343057
 Other MAC204211292266
 Fludarabine RIC165124344397
 Other RIC3435513
TBI1.00.79.11
 No4092377361159
 Yes551285397115222
  • ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CMV, cytomegalovirus; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; RIC, reduced-intensity conditioning; TBI, total-body irradiation.